Decreased NADPH: Cytochrome P-450 Reductase Activity and Impaired Drug Activation in a Mammalian Cell Line Resistant to Mitomycin C under Aerobic but not Hypoxic Conditions

Cancer Research

Volumn 50, Issue 15, 1990, Pages 4692-4697

  Hoban, Paul R ^a   Walton, Michael I ^b   Robson, Craig N ^a,d   Godden, Judith ^c   Stratford, Ian J ^c   Workman, Paul ^b   Harris, Adrian L ^a,d   Hickson, Ian D ^a,d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 N (DIMETHYLAMINOMETHYLENE)MITOMYCIN C; DOXORUBICIN; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; VINCRISTINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CHO CELL; DRUG RESISTANCE; HAMSTER; HYPOXIA; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL;

AEROBIOSIS; ALKYLATING AGENTS; ANAEROBIOSIS; ANIMAL; ANOXIA; BIOTRANSFORMATION; CELL LINE; CELL SURVIVAL; CRICETULUS; DRUG RESISTANCE; FEMALE; HAMSTERS; MITOMYCIN; MITOMYCINS; NADPH-FERRIHEMOPROTEIN REDUCTASE; OVARY; SUPPORT, NON-U.S. GOV'T; ULTRAVIOLET RAYS;

EID: 0025352024     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Crooke, S. T., and Bradner, W. T. Mitomycin C: a review. Cancer Treat. Rev., 5: 121–139, 1976.
2. Bakowski, M. T., and Crouch, J. C. Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat. Rev., 10: 159–172, 1983.
3. Wise, G. R., Kuhn, I. N., and Godfrey, T. E. Mitomycin C in large infrequent doses in breast cancer. Med. Pediatr. Oncol., 2: 55–60, 1976.
4. Radford, J. A., Knight, R. K., and Rubens, R. D. Mitomycin C and vinblastine in the treatment of advanced breast cancer. Eur. J. Cancer Clin. Oncol., 21: 1475–1477, 1985.
5. Kennedy, K. A., Rockwell, S., and Sartorelli, A. C. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res., 40:2356–2360, 1980.
6. Rockwell, S. Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo. J. Natl. Cancer Inst., 71: 765–771, 1983.
7. Coleman, C. N., Bump, E. A., and Kramer, R. A. Chemical modifiers of cancer treatment. J. Clin. Oncol., 6: 709–733, 1988.
8. Workman, P. Optimized treatment of hypoxic tumour cells. In: L. Domellof (ed.), Cancer Treatment: Symptom Control, Nutrition, Chemotherapy, pp. 79–102. New York: Springer-Verlag, 1989.
9. Iyer, V. N., and Szybalski, W. Mitomycins and porfiromycin: Chemical mechanism of activation and cross-linking of DNA. Microbiology, 50: 355–362, 1963.
10. Tomasz, M., and Lipman, R. Reductive metabolism and alkylating activity of mitomycin C induced by rat liver microsomes. Biochemistry, 20: 5056–5061,1981.
11. Tomasz, M., Chowdary, D., Lipman, R. Shimotakahara, S., Veiro, D., Walker, V., and Verdine, G. L. Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of the major covalent adduct. Proc. Natl. Acad. Sei. USA, 83:6702–6706, 1986.
12. Tomasz, M., Lipman, R., Chowdary, D., Pawlak, J., Verdine, G. L., and Nakanishi, K. Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science (Wash. DC), 235:1204–1208, 1987.
13. Schwartz, H. Pharmacology of mitomycin C: III. In vitro metabolism by rat liver. 250–258, 1962.
14. Kennedy, K., Sligar, S. G., Polomski, L., and Sartorelli, A. C. Metabolite activation of mitomycin C by liver microsomes and nuclei. Biochem. Pharmacol., 31: 2011–2016,1982.
15. Komiyama, T., Oki, T., and Inui, T. Activation of mitomycin C and quinone drug metabolism by NADPH-cytochrome P-450 reductase. J. Pharmacobiodyn., 2:407–410, 1979.
16. Keyes, S. R., Fracasso, P. M., Heimbrook, D. C., Rockwell, S., Sligar, S. G., and Sartorelli, A. C. Role of NADPHxytochrome c reductase and DT diaphorase in the biotransformation of mitomycin C. Cancer Res., 44:5638–5643, 1984.
17. Pan, S-S., Iracki, T., and Bachur, N. R. DNA alkylation by enzyme-activated mitomycin C. Mol. Pharmacol., 29: 622–628, 1986.
18. Pritsos, C. A., and Sartorelli, A. C. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res., 46:3528–3532, 1986.
19. Robson, C. N., Harris, A. L., and Hickson, I. D. Isolation and characterization of Chinese hamster ovary cell lines sensitive to mitomycin C and bleomycin. Cancer Res., 45: 5304–5309, 1985.
20. Robson, C. N., Hoban, P. R., Harris, A. L., and Hickson, I. D. Cross sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines. Cancer Res., 47: 1560–1565, 1987.
21. Cooke, B. C., Fielden, E. M., Johnson, M., and Smithen, C. E. Polyfunctional radiosensitizers. I. Effects of a nitroxyl biradical on the survival of mammalian cells in vitro. Radiat. Res., 65:152–162, 1976.
22. Stratford, I. J., Walling, J. M., and Silver, A. R. J. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action. Br. J. Cancer, 53:339–344,1986.
23. O'Neill, P., Jenkins, T. C., Stratford, I. J., Silver, A. R. J., Ahmed, I., McNeil, S. S. Fielden, E. M. and Adams, G. E. Mechanism of action of some bioreducible 2-nitroimidazoles: comparison of in vitro cytotoxicity and ability to induce DNA strand breakage. Anti-Cancer Drug Design, 1: 271–280, 1987.
24. Stratford, I. J., and Stephens, M. A. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radiat. Oncol. Biol. Phys., 16: 973–976, 1989.
25. Walton, M. I., and Workman, P. Nitroimidazole bioreductive metabolism: quantitation and characterization of mouse tissue benzimidazole nitroreductases in vivo and in vitro. Biochem. Pharmacol., 236: 887–896, 1987.
26. Phillips, A. H., and Langdon, R. G. Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J. Biol. Chem., 237: 2652–2660, 1962.
27. Ernster, L. DT diaphorase. Methods Enzymol., 10: 309–317, 1967.
28. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265–275, 1951.
29. Harker, W. G., and Sikic, B. I. multidrug (pleiotropic) resistance in Doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res., 45:4091–4096, 1985.
30. Bhalla, K., Hindenburg, A., Taub, R. N., and Grant, S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res., 45: 3657–3662,1985.
31. Giavazzi, R., Kartner, N., and Hart, I. R. Expression of cell surface P-glycoprotein by an Adriamycin-resistant murine fibrosarcoma. Cancer Chemother. Pharmacol., 13:145–147, 1984.
32. Dorr, R. T., Liddil, J. D., Trent, J. M., and Dalton, W. S. Mitomycin C resistant LI 210 leukemia cells: association with pleiotropic drug resistance. Biochem. Pharmacol., 36: 3115–3120, 1987.
33. Weissbasch, A., and Lisio, A. Alkylation of nucleic acids by mitomycin C and porfiromycin. Biochemistry, 4: 196–200, 1965.
34. Crooke, S. T., and Bradner, W. T. Mitomycin C: a review. Cancer Treat. Rev., 5; 121–139,1976.
35. Danishefsky, S., and Ciufolini, M. Leucomitomycins. J. Am. Chem. Soc., 706:6424–6425,1984.
36. Pan, S-S., Andrews, P. A., and Glover, C. J. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J. Biol. Chem., 259: 959–966, 1984.
37. Dorr, R. T., Bowden, G. T., Alberts, D. S., and Liddil, J. D. Interactions of mitomycin C with mammalian DNA detected by alkaline elution. Cancer Res., 45: 3510–3516, 1985.
38. Bachur, N. R., Gordon, S. L., and Gee, M. V. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res., 38: 1745–1750,1978.
39. Tomasz, M. H202 generation during the redox cycle of mitomycin C and DNA-bound mitomycin C. Chem.-Biol. Interact., 13: 89–97, 1976.
40. Lind, C., Hochstein, P., and Ernster, L. DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch. Biochem. Biophys., 216: 178–185, 1982.
41. Atallach, A., Landolph, J. R., and Hochstein, P. DT diaphorase and quinone detoxification. Chem. Scripta, 27A: 141–144, 1987.
42. Schlager, J. J., and Powis, G. Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone-acceptor) oxidoreductase. Cancer Chemother. Pharmacol., 22: 126–130, 1988.
43. Workman, P., Walton, M. I., Powis, G., and Schlager, J. J. DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? Br. J. Cancer, 60:800–802, 1989.
44. Dulhanty, A. M., Li, M., and Whitmore, G. F. Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation. Cancer Res., 49: 117–122, 1989.
45. Marshall, R. S., Paterson, M. C., and Rauth, A. M. Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions. Br. J. Cancer, 59: 341–346, 1989.
46. Wilson, J. K. V., Long, B. H., Chakrabarty, S., Brattain, D. E., and Brattain, M. G. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells. Cancer Res., 45: 5281–5286, 1985.
47. Chakrabarty, S., Danels, Y. J., Long, B. H., Wilson, J. K. V., and Brattain, M. G. Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY 25282. Cancer Res., 46: 3456–3458, 1986.
48. Workman, P., and Walton, M. I. Enzyme-directed bioreductive drug development. In: G. E. Adams, A. Breccia, E. M. Fielden, and P. Wardman (eds.), Selective Activation of Drugs by Redox Processes. New York: Plenum Publishing Corp., 1990.